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ARTICLE

OPEN

Associations between polygenic risk, negative symptoms, and
functional connectome topology during a working memory
task in early-onset schizophrenia

1234567890():,;

Mengjie Deng1,2, Zhening Liu1,2, Wen Zhang1,2, Zhipeng Wu1,2, Hengyi Cao3,4, Jie Yang

1,2 ✉

and Lena Palaniyappan5,6,7,8

Working memory (WM) deﬁcit in schizophrenia is thought to arise from a widespread neural inefﬁciency. However, we do not know
if this deﬁcit results from the illness-related genetic risk and inﬂuence the symptom burden in various domains, especially in
patients who have an early onset illness. We used graph theory to examine the topology of the functional connectome in
99 subjects (27 early-onset schizophrenia (EOS), 24 asymptomatic siblings, and 48 healthy subjects) during an n-back task, and
calculated their polygenic risk score (PRS) for susceptibility to schizophrenia. Linear regression analysis was used to test associations
of the PRS, clinical symptoms, altered connectomic properties, and WM accuracy in EOS. Indices of small-worldness and segregation
were elevated in EOS during the WM task compared with the other two groups; these connectomic aberrations correlated with
increased PRS and negative symptoms. In patients with higher polygenic risk, WM performance was lower only when both the
connectomic aberrations and the burden of negative symptoms were higher. Negative symptoms had a stronger moderating role
in this relationship. Our ﬁndings suggest that the aberrant connectomic topology is a feature of WM task performance in
schizophrenia; this relates to higher polygenic risk score as well as higher burden of negative symptoms. The deleterious effects of
polygenic risk on cognition are played out via its effects on the functional connectome, as well as negative symptoms.
Schizophrenia (2022)8:54 ; https://doi.org/10.1038/s41537-022-00260-w

INTRODUCTION
Schizophrenia is a multigene disorder with high heritability1,2,
with more than 145 independent genomic risk loci being
associated with this illness in genome-wide association studies
(GWAS)3,4. The cumulative effect of these genes is thought to
contribute to the phenotype of core symptoms and cognitive
deﬁcits seen in patients. A polygenic risk score (PRS) based on the
GWAS results was developed to measure the additive effects of
multiple risk genes5–7. The genetic risk for schizophrenia varies
among patients based on the age of illness onset; higher genetic
risk burden is thought to hasten the age of onset, so early-onset
patients display higher genetic burden than patients with
adulthood onset schizophrenia8,9.
The unaffected siblings of patients with schizophrenia share
50% genetic background with patients10. They share certain
endophenotypes that are often subtle, nonclinical features such as
cognitive impairment11, neurological soft signs12, and brain
structural and functional abnormalities13. Compared with patients,
the unaffected siblings were free of antipsychotics and chronic
disease course inﬂuence. Therefore, investigating these endophenotypes in unaffected siblings may help to acknowledge the
clinical or biological ﬁndings that are more closely related to risk
genes than the disorder itself.
As a key feature of schizophrenia, working memory (WM) deﬁcit
is also an important endophenotype of schizophrenia14. The WM
deﬁcit not only has been observed in patients with schizophrenia
throughout the prodromal stage as well as the psychotic phase in

the disease, which persists even after symptomatic remission
resulting in a lifelong cognitive burden, but also has been
observed in their unaffected siblings15,16. Substantial research on
the heritability of neurocognition has estimated that the
heritability of working memory is around 33–64%17–19. Furthermore, previous studies20,21 probing the neural mechanism of WM
impairment in schizophrenia and their siblings have revealed the
continuity or a similar pattern of neural abnormities between
these two groups. However, as with some siblings who have
subtle symptoms, it is difﬁcult to distinguish whether these neural
abnormities that merely related to genetic risks or also associated
with these subtle clinical symptoms.
The neural inefﬁciency phenomenon during WM performance
has been widely endorsed in schizophrenia22. There is a left shift of
the inverted U-shaped model of WM-related cortical engagement
in schizophrenia23. Previous studies have indicated that patients
tend to adopt a compensating neural strategy to facilitate the
improvement of WM performance at higher loads but this energyhungry process is not sustainable, driving up the burden of
negative symptoms23,24. Negative symptoms have been demonstrated to affect the WM performance and mediate the relationship
between WM deﬁcits and functional outcome25–27. In our prior
work, we investigated the neural efﬁciency of the whole-brain
functional connectome during the WM task in schizophrenia by
employing graph theory tools28. Patients showed a more homogeneous network organization compared with HCs, but with
elevated modular segregation of topologically proximal brain
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Table 1.

Demographic, neuropsychological, and clinical data.

Items

EOS (n = 27)

SB (n = 24)

HCs (n = 48)

Age (Years)

18.37 (0.63)

19.92 (0.67)

19.73 (0.47)

1.89

0.16

N/A

Gender (M/F)

14/13

8/16

28/20

4.03

0.133

N/A

Education (Years)

10.63 (0.5)

11.5 (0.5)

12.5 (0.37)

5.0a

0.0085a

EOS < HCs; p = 0.0026;

Illness duration (Month)

25.6 (17.7)

N/A

N/A

N/A

N/A

N/A

Total dosage (mg)

399.84 (342.2)

N/A

N/A

N/A

N/A

N/A

PANSS_total
PANSS_N

65.89 (25.05)
17.89 (9.2)

N/A
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A
N/A

F/χ2

P value

Post Hoc Signiﬁcance

PANSS_P

13.67 (7.4)

N/A

N/A

N/A

N/A

N/A

PANSS_G

30.8 (13.4)

N/A

N/A

N/A

N/A

N/A

PANSS_S

3.52 (1.3)

N/A

N/A

N/A

N/A

N/A

SAPS

22.2 (21.1)

N/A

N/A

N/A

N/A

N/A

SANS

43.7 (35.2)

N/A

N/A

N/A

N/A

N/A

ACC_2back

0.7 (0.14)

0.77 (0.18)

0.84 (0.12)

8.55a

0.0004a

EOS < HCs; p = 0.0001;
SB < HCs; p = 0.049;

ACC_0back

0.88 (0.16)

0.87 (0.2)

0.94 (0.09)

2.53

0.09

N/A

RTC_2back (ms)
RTC_0back (ms)

709.6 (150.7)
532.6 (115.2)

715.1 (154.5)
548.1 (86.6)

638.1 (124.5)
496.2 (78.4)

3.02
2.6

0.054
0.08

N/A
N/A

n number, PANSS Positive and Negative Syndrome Scale, PANSS_N the sum score of all negative items in the Positive and Negative Syndrome Scale, PANSS_P
the sum score of all positive items in the Positive and Negative Syndrome Scale, PANSS_G the sum score of all general items in the Positive and Negative
Syndrome Scale, PANSS_S the sum score of all supplemental items in the Positive and Negative Syndrome Scale, SAPS the Scale for the Assessment of Positive
Symptoms, SANS the Scale for the Assessment of Negative Symptoms, N/A not available. ACC_2back accuracy under the 2-back load, ACC_0back accuracy under
the 0-back load, RTC_2back response time under the 2-back load, RTC_0back response time under the 0-back load, EOS early-onset schizophrenia, SB siblings,
HCs healthy controls.
a
Signiﬁcantly different among three groups.

regions rather than the global integration that is critical for the WM
task29. This inefﬁciently reconﬁgured pattern of the whole-brain
functional connectome in schizophrenia replicated across different
datasets with heterogeneous clinical data and robust across
different parcellation schemes. However, we do not know if this
aberrant connectome conﬁguration is also seen in siblings that are
unaffected and relates to PRS of schizophrenia.
In the current study, we aim to explore whether the inefﬁcient
connectome origination pattern emerges in siblings and whether
this pattern is genetically or clinically related to the disease. To this
end, we employed the graph theory methods to investigate the
connectome organization of patients with early-onset schizophrenia (EOS) and their siblings during WM tasks. We also calculated
their PRS scores to identify the intermediate neurophysiological
phenotypes that may be affected by these cumulative genetic
effects, which may help to better understand the functional role of
these genetic variations. The linear regression model was adopted
to probe the association between the PRS, clinical symptoms,
connectome topology, and WM performance. To the best of our
knowledge, this is the ﬁrst study assessing the functional
connectome proﬁle in the EOS and their siblings during WM task,
and further probing the relationship between this proﬁle with the
genetic risks, clinical symptoms, and WM performances.
RESULTS
Participant characteristics
As shown in Table 1, one-way analysis of variance revealed a
signiﬁcant omnibus difference in education (F2,98 = 5.0, p =
0.0085), and accuracy of WM under 2-back load (F2,89 = 8.42,
p = 0.0005) across all groups, but no signiﬁcant omnibus
difference in age (F2,98 = 1.85, p = 0.16) and gender (χ2 = 4.03,
p = 0.133). Post hoc tests revealed the education years of HCs
were longer than that of EOS (p = 0.0026), and the accuracy
Schizophrenia (2022) 54

of WM under 2-back load of HCs was higher than that of EOS
(p = 0.0001) and SB (p = 0.049).
Genetic data
In our current study, due to the limited number of subjects, there
was no signiﬁcant omnibus difference in the synthesized PRS
across all three groups (EOS mean (SD) = 25.63 (70.7), SB mean
(SD) = 21.52 (84.37), HCs mean (SD) = −30.28 (96.4)).
Network properties
One-way analysis of variance revealed a signiﬁcant omnibus
difference in sigma across all diagnostic groups (EOS mean (SD) =
1.421(0.031), SB mean (SD) = 1.27(0.033), HCs mean (SD) = 1.3
(0.023), F2,98 = 6.66, p = 0.002, see Fig. 1a and Table 2). Post hoc
tests revealed signiﬁcantly increased sigma in EOS compared to SB
(p = 0.0012), as well as HCs (p = 0.0029).
One-way analysis of variance indicated a signiﬁcant omnibus
difference in gamma across all diagnostic groups (EOS mean (SD) =
1.52(0.032), SB mean (SD) = 1.37(0.034), HCs mean (SD) = 1.39
(0.024), F2,98 = 6.6, p = 0.002, see Fig. 1b). Post hoc tests revealed
signiﬁcantly increased gamma in EOS compared with SB (p =
0.0015), as well as HCs (p = 0.0024).
The omnibus alteration of lambda was not observed across
all diagnostic groups (EOS mean (SD) = 1.06(0.004), SB mean
(SD) = 1.073(0.005), HCs mean (SD) = 1.065 (0.0033), F2,98 =
2.25, p = 0.11, see Fig. 1c).
At the regional level, we did not observe signiﬁcant omnibus
difference in the regional clustering coefﬁcient across all
diagnostic groups after multiple comparison corrected.
Exploratory analysis
Correlation analysis. We observed the signiﬁcant correlation
between the synthesized PRS with the altered global network
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Fig. 1 Global properties of the whole-brain functional connectome calculated on Power atlas in three diagnostic groups. The range of
densities is 0.1:0.02:0.5, and symbol “*” represents p < 0.05. a Comparison of mean sigma across densities among three groups; b comparison
of mean gamma across densities between three groups; c comparison of mean lambda across densities among three groups.

Table 2.

Global network measures showing signiﬁcant omnibus alteration.

Items

EOS (n = 27)

SB (n = 24)

HCs (n = 48)

F/χ2

P value

Post Hoc Signiﬁcance

Sigma

1.421 (0.031)

1.27 (0.033)

1.3 (0.023)

6.61a

0.002a

Gamma

1.52 (0.032)

1.37 (0.034)

1.39 (0.024)

6.66a

0.002a

EOS > SB; p = 0.0012;
EOS > HCs; p = 0.0029;
EOS > SB; p = 0.0015;
EOS > HCs; p = 0.0024;

Lambda

1.06 (0.004)

1.073 (0.005)

1.065 (0.0033)

2.25

0.11

N/A

n number, EOS early-onset schizophrenia, SB siblings, HCs healthy controls, HCs healthy controls.
Sigma or small-worldness is the ratio of gamma (normalized clustering coefﬁcient) over lambda (normalized characterized path length).
a
Signiﬁcantly different among three groups.

measures—sigma (p = 0.029; r = 0.5) and gamma (p = 0.028; r =
0.504), as well as the signiﬁcant correlation between the negative
symptoms with the altered global network measures—sigma (p =
0.036; r = 0.412) and gamma (p = 0.041; r = 0.404). There were no
association among other parameters (see Fig. 2a1 and a2).

Moderation analysis. We were interested in exploring whether
reduced WM performance in EOS results from the illness-related
genetic risk (PRS), and if the symptom burden and/or connectomic
aberrations inﬂuence this relationship. As our linear regression
analysis indicated a signiﬁcant relationship between the
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Fig. 2 Exploratory analysis. The symbol “*” represents p < 0.05. a Correlation analysis among synthesized PRS, clinical symptoms (including
SumN [negative symptom scores] and SumP [positive symptom scores]), altered network measures (including sigma and gamma), and WM
performance; b Linear regression analysis among the synthesized PRS, negative symptoms, sigma, and WM performance.

connectomic measures and negative symptoms as well as
synthesized PRS, we explored a chain of moderation models to
test the association between the synthesized PRS, a static measure
as the independent variable and negative symptoms, and altered
global network measures—both of which are variable over time—
as mediators to predict WM performance (dependent variable). As
shown in Fig. 2b1 and b2, in EOS, sigma moderated the
relationship between synthesized PRS and WM performance
(p = 0.045, β = 0.0004); and negative symptoms moderated the
relationship between synthesized PRS and WM performance (p =
0.0016, β = 0.0001). Then, we constructed a moderation model
(model 2 in PROCESS), and set both the negative symptoms and
sigma as moderator variables. As shown in Fig. 2b3, in EOS, we
observed the also negative symptoms (p = 0.037, β = −0.0001),
but not the sigma (p = 0.495, β = −0.0001), moderated the
relationship between synthesized PRS and WM performance.
When we treated the gamma as a moderator variable, we
observed results similar to those described above (see Supplemental material S2).
DISCUSSION
To our knowledge, this is the ﬁrst study combining the sibling and
genetic risk data to demonstrate functional connectome topology
changes associated with WM deﬁcits in EOS. We report three main
ﬁndings. Firstly, there is a signiﬁcant increase in small-worldness in
EOS compared with their siblings and HCs; this increase is driven
by the local clustering but not the global integration. Secondly,
these connectomic aberrations are associated with an increase in
polygenic risk and negative symptoms. Thirdly, the polygenic risk
Schizophrenia (2022) 54

inﬂuenced the WM performance through connectomic aberrations and negative symptoms, with negative symptoms being a
more inﬂuential moderator of the polygenic risk -WM performance
relationship than the connectome topology.
We observed that patients with EOS showed an increased smallworldness compared with siblings and HCs, and this increase was
attributed to the elevated segregation but with no concomitant
increase in integration. The current ﬁndings are consistent with
our previous observations28 which supported the increased smallworldness accompanied by the elevated segregation in three
datasets across early-onset, adult-onset, and chronic schizophrenia during the WM task. As connectome-level functional integration is seen as critical for working memory29, the increased
segregation that we observed during the WM task may reﬂect a
neural integrative inefﬁciency in schizophrenia; thus, the observed
neural activity cannot effectively and sustainably promote
cognitive performance, especially at higher loads.
There were no group differences between siblings and HCs in
network measures with the omnibus alteration. Contrary to our
ﬁndings, previous studies have demonstrated the continuity (i.e., a
similar pattern) of neural abnormalities among patients with
schizophrenia and siblings during the WM task. For example,
Landin-Romero et al.20 have documented that both the patients
and the siblings showed a signiﬁcant failure of deactivation in the
medial frontal cortex compared with the HCs; Loeb et al.21 have
reported that siblings had altered functional activation and
connectivity intermediate between patients with childhoodonset schizophrenia and controls in the frontoparietal and
cortico-striatal regions. Nonetheless, previous studies also
reported inconsistent ﬁndings especially when the sibling group
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was more carefully separated. Choi et al.30 have observed that,
during the WM task, healthy ﬁrst-degree relatives of patients
(genetic high risk or GHR) showed increased activation but the
ultra-high-risk groups with prodromal symptoms (UHR) and
patients showed decreased activation in the frontoparietal
network compared with HCs. In that study, the ordinal pattern
of the frontoparietal network activation was GHR > HCs>UHR ≈
patients. Therefore, the observed continuity (i.e., a similar pattern)
of neural deﬁcits among patients with schizophrenia and siblings
may associate with the subtle clinical symptoms in the recruited
siblings. In the context of Choi et al. study30, we speculate that the
altered functional connectome topology associated with WM
deﬁcits in schizophrenia may relate more to clinical expression
rather than genetic burden.
In the EOS, the increased small-worldness and segregation
correlated with increased PRS and negative symptoms, and these
network measures and negative symptoms can separately
moderate the association between PRS and WM performance.
We observed that increased small-worldness and segregation
have a positive effect on WM performance in patients with higher
genetic risks. This ﬁnding resonates with our prior study28 that
demonstrated the more severely affected patients (e.g., higher
genetic risk or more severe clinical symptoms), can make modest
improvements in their WM performance only when higher
physiological efforts are spent, but the accuracy level thus
achieved would still be considerably lower than what the healthier
individuals achieve with less effort. Here we ﬁnd higher genetic
risk in those with more serious negative symptoms improved
better WM performance modestly. Considering the negative
symptoms positively correlated with the network properties, we
speculate this performance promotion effect of polygenic factors
may indeed reﬂect the higher physiological efforts (i.e., processing
cost) in EOS. In fact, in the multivariate moderation analysis, when
variance due to connectome aberrations was accounted for, PRS
in patients with higher negative symptoms related to reducing
WM performance, i.e., not “performance-enhancing” anymore.
These constellations may indicate that the genetic risk has an
effect on the WM performance through the negative symptoms
and functional connectome organization, and the negative
symptoms have a critical important moderating role, exerted in
part, through the functional connectome topology.
LIMITATIONS
There are several limitations in the present study. First, despite
their suitability for sibling-paired samples, there are many
challenges in recruiting EOS subjects; this study was limited to a
single site and we lacked another independent dataset to testify
the replication of our study. Second, we did not ﬁnd signiﬁcant
difference in PRS among EOS, SB, and HCs, which may be a type-2
error. Future studies with larger sample size and replication
dataset will be needed to further validate our ﬁndings. We urge
the readers to treat these as hypothesis-forming observations for
future conﬁrmation. Finally, as all patients in our study were
treated with antipsychotics and their illness duration was not
restricted when they were recruited, we urge caution when
attempting to generalize these ﬁndings to untreated cohorts.
CONCLUSIONS
In the present study, we demonstrate that the architecture of the
functional connectome is altered in early-onset schizophrenia
during a WM task, and this abnormality tracks the burden of
negative symptoms. The polygenic risk for schizophrenia inﬂuences cognitive performance indirectly by increasing the negative
symptom burden, as well as through its effects on the functional
connectome. In the presence of higher polygenic risk, efforts to

address negative symptoms may have more impact on subsequent cognitive rehabilitation.
METHODS
Participants
The procedures of the present study were approved by the medical ethics
committee of the Second Xiangya Hospital, Central South University,
Changsha, China. Prior to obtaining consent, two licensed psychiatrists
with at least 2 years of working experience in psychiatry department
ascertained the capacity of all potential participants to provide informed
consent. All participants were right-handed native Chinese and they
signed written informed consent prior to study enrollment. All study
procedures were in strict accordance with the Declaration of Helsinki.
A total of 39 patients with early-onset schizophrenia (EOS) and 33 of
their unaffected siblings (SB) were recruited from the Second Xiangya
Hospital of Central South University. Under the assessment of clinical
psychiatrists, all patients met the schizophrenia criteria of Structured
Clinical Interview of DSM-IV (SCID) and the clinical symptoms of patients
were assessed by using the Positive and Negative Symptom Scale
(PANSS)31, the Scale for the Assessment of Positive Symptoms (SAPS)32
and the Scale for the Assessment of Negative Symptoms (SANS)33. The
exclusion criteria for patients with EOS were: (1) age <14 or >45 years old;
(2) the age of ﬁrst onset >18 years old; (3) history of alcohol or substance
dependence; (4) neurological disorders, former recorded brain injury or
physical diseases; (5) history of receiving electroconvulsive therapy; (6) any
contraindications for magnetic resonance imaging (MRI) scanning; (7)
benzodiazepine treatment, if any, stopped for at least 24 h before
scanning. The exclusion criteria for SB were the same as those for patients
except that they did not meet the DSM-IV criteria for any mental disorders.
Fifty-six age- and sex-matched healthy controls (HCs) were recruited
from the local community and were assessed using the SCID non-patient
edition. The exclusion criteria for HCs were the same as those for
patients except that they did not meet the DSM-IV criteria for any mental
disorders and their ﬁrst-degree relatives had no history of any known
mental disorders.

MRI data acquisition and pre-processing
All neuroimaging data were obtained on a Siemens Allegra 3-T scanner
with a gradient-recalled echo-planar imaging pulse sequence. And the
parameters were showed as followed: repetition time (TR) = 2000 ms,
echo time (TE) = 30 ms, ﬂip angle = 90°, FOV = 240 × 240 mm2, acquisition matrix = 64 × 64, slices = 32, slice thickness = 5 mm, gap =0 mm,
and total volumes = 253.
Imaging data were preprocessed and analyzed by the DPABI toolbox34.
The ﬁrst ﬁve images were discarded for scanner stabilization, and a total of
248 volumes were obtained for preprocessing. The remaining volumes
were slice-time corrected, realigned to correct for head motion, spatially
normalized into the brain template of Montreal Neurologic Institute (MNI),
and smoothed (FWHM = 8 mm). Linear detrending was performed and
followed by nuisance covariates regression including 12 head motion
parameters (including derivatives), white matter, and CSF signals. As recent
research has shown illness-related variance in the global signals35, the
global signal was not removed. Displaced volumes (framewise displacement >0.5 mm) were interpolated by nearest-neighbor interpolation36,37.
Samples were excluded if they met the following criteria: (1) head motions
>2.5 mm translation or >2.5° rotation; (2) fMRI data visually examined by
experienced data analysts that failed to normalize to MNI space. After
quality control, a total of 28 EOS, 25 SB, and 48 HCs were included in the
ﬁnal analysis. No signiﬁcant difference was found in framewise displacement (total number of interpolated volumes) across all three groups (EOS
mean(SD) = 7.88(11.09), SB mean(SD) = 8.33(11.48), HCs mean(SD) = 9.28
(13.9), F2,98 = 0.11, p = 0.89).

Genetic data processing
We collected whole blood samples of all subjects and extracted genomic
DNA by the EZgene Blood gDNA Miniprep Kit. Next, we performed wholegenome genotyping by using the standard Illumina genotyping protocol
on Illumina Asian Screening Array (ASA) Bead Chip. All genetic data
underwent standard quality control using PLINK 1.938. We removed the
sample with higher missing genotype rate in each pair that more similar
genotypes were identiﬁed by calculating the pairwise identity-by-descent
than we would expect in a random sample, removing 1 individual from the
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dataset of EOS and 1 individual from the dataset of SB. And a total of 27
EOS, 24 SB, and 48 HCs were left in the present study. Next, a principal
component analysis (PCA) was conducted to control the population
stratiﬁcation using EIGENSTART39,40 on a linkage disequilibrium (LD)
pruned set of autosomal SNPs obtained by carrying out LD pruning with
PLINK and removing ﬁve long-range LD regions with the Hap Map phase 3
reference dataset41. Finally, we excluded the SNPs with missing genotype
rates <0.95, a minor allele frequency (MAF) < 0.01, or a signiﬁcant
departure from Hardy-Weinberg Equilibrium (HWE, P < 1.0 × 10−6), leaving
about 396,343 SNPs.
Genotypes after quality control were performed imputations for nongenotyped genetic variants using the SHAPEIT42 and IMPUTE43 with the
Phase 3 multi-ethnic 1000 Genomes Projects panel, as the reference based
on the human genome assembly hg19 (https://mathgen.stats.ox.ac.uk/
impute/1000GP_Phase3.html). We removed SNPs with imputation quality
control <0.8, missing genotyping rate <0.95, MAF < 0.01, or signiﬁcant
departure from HWE (P < 1.0 × 10–6). About 7,672,168 SNPs survived the
pruning procedures and were used to calculate the PRS score.
The PRS analysis was performed using the PRSice toolbox44 based on
the GWAS results from the Psychiatric Genomics Consortium (https://www.
med.unc.edu/pgc/results-and-downloads). All matched SNPs between the
base and target datasets were clumped based on the LD threshold of R2 <
0.2 within a 500 kb window. The scores were computed as the total of
genome-wide risk alleles for each participant, weighted by the corresponding odds ratios to schizophrenia. We calculated PRSs with a set of
thresholds [5 × 10−8; 5 × 10−5; 5 × 10−5; 0.1; 0.1001:1 × 10−4; 0.5 1] (6002
PRS in total). We used the PCA method to do dimension reduction, and
retrieve the ﬁrst component (explained 89.3% of total variance) to
represent the synthesized PRS.

Network construction
The WM paradigm adopted in the present study comprised two load
conditions (0-back and 2-back, the details were given in Supplementary
material S1). To construct the process of functional connection matrix, only
the fMRI volumes obtained in the four blocks of 2-back performance were
concatenated45, as the 0-back load is not considered a task of WM. We
extracted the mean time series from each of the 264 nodes with 6 mm
spheres deﬁned by the Power atlas46. We calculated the Pearson
correlation coefﬁcients of the time series for each pair of ROIs to generate
a 264 × 264 symmetric matrix was for each participant and applied the
Fisher z transformation to convert the resultant matrix into normally
distributed scores. We also controlled the variance caused by the linear
effects of demographic data including age, gender, and education years to
derive the corrected symmetric matrix.
With using scripts from the Brain Connectivity Toolbox (http://www.
brain-connectivity-toolbox.net/), we calculated global network measures
including sigma (small-worldness), lambda (normalized characterized path
length), gamma (normalized clustering coefﬁcient), and regional network
measure—clustering coefﬁcient (strongly associated with gamma) on the
264 × 264 weighted adjacency matrices at a series of network densities
(0.1:0.02:0.5). The sigma is a ratio of gamma to lambda (ie., sigma =
gamma/lambda). The normalized topological properties—gamma and
lambda, must be benchmarked against corresponding mean values of null
random graphs (i.e., gamma = C/Cnull and lambda = L/Lnull, where C
indicates the clustering coefﬁcient, and L indicates the path length).
Wherein, we generated 20 null random networks, with the same number
of nodes, degree, and degree distribution as the network of interest.

Statistical analysis
We applied the one-way analysis of variance (ANOVA) and χ2 tests to
detect group differences in demographic, neuropsychological characteristics, and behavioral data. As for network metrics, we employed the
functional data analysis (FDA)47 to synthesize values across densities. In
the FDA, each network metric curve is treated as a function (y = f(x)), and
the sum of differences in y-values is calculated across densities. Then,
the synthesis network metrics were subsequently allowed to the oneway ANOVA analysis, and followed by the post hoc comparison
procedure when signiﬁcant main effects were present. Furthermore,
we adopted the Benjamini-Hochberg method (FDR corrected) with
p < 0.05 for multiple comparison to generate statistical maps of regional
network metrics.
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Exploratory analysis
Correlation analysis. We conducted the correlation analysis between any
two of the four types of parameters, including the synthesized PRS, altered
global network properties, clinical symptoms (positive and negative
symptoms), and WM performance.
Moderation analysis. We adopted linear regression analysis to test the
association of the synthesized PRS, WM performance, clinical symptoms, and altered global network properties in the EOS. The linear
regression analysis was conducted on the PROCESS 3.0 macro that was
embedded in SPSS22, with a 5000 bias-corrected bootstrap sample for
signiﬁcance testing.
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The data that support the ﬁndings of this study are available from the corresponding
author upon reasonable request.
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